Technology Commercialization Group, LLC (TCG), the international advisory firm providing interim management and consultancy services for partnering and expansion capital in the pharmaceuticals, biotech and biomedical industries, with offices in the US and Germany, is pleased to announce that Oliver Boucher, based in Brussels, Begium has joined the Group as a Partner to provide additional European support.

Oliver has over 30 years of experience in the pharmaceutical, biotechnology and diagnostics sectors of the healthcare industry. He received an MA in genetics and molecular biology from Cambridge University and earned an MBA from INSEAD Business School.

Before joining TCG in 2016, Oliver was the Managing Director of the specialist advisory firm, TCF Consulting for 3 years, building on previous experience in business development and commercial leadership positions at Novartis, GSK and senior management roles in multiple start-ups in Europe.  He played a key role in the $90 million sale of Vivacta, a diagnostic start-up to Novartis where he advised on post-acquisition integration. He has held positions in North America, Ireland, UK, France and Belgium. Before joining the industry, he was a patent attorney in London, Montreal and Paris.

Oliver brings to TCG commercial development experience in a range of therapeutic areas including anti-infectives, cancer, cardiovascular, gastro-intestinal and inflammation.  He also has business development and partnering experience in diverse fields including small molecules, biologicals, oral drug delivery, vaccines, and in-vitro diagnostics. Mr. Boucher has a global network for business building, value realization and partnering.